GENETIC DETERMINANTS OF TAC CHEMOTHERAPY RESPONSE IN TRIPLE NEGATIVE BREAST CANCER PATIENTS

AHMAD AIZAT BIN ABDUL AZIZ

UNIVERSITI SAINS MALAYSIA

2018

GENETIC DETERMINANTS OF TAC CHEMOTHERAPY RESPONSE IN TRIPLE NEGATIVE BREAST CANCER PATIENTS

by

AHMAD AIZAT BIN ABDUL AZIZ

Thesis submitted in fulfillment of the requirements

for the degree of

Doctor of Philosophy

September 2018

ACKNOWLEDGEMENTS

I would like to say Alhamdulillah, for giving me the strength, good health and patience in completing this study

I would like to express my greatest appreciation and gratitude to my supervisor, Professor (Dr) Ravindran Ankathil, Human Genom Centre, USM for his supervision, continuous support and also for his trust in me throughout my study. Thank you for being a great supervisor in giving a lot of opportunities and encouragement for me to improve my skills and gaining new knowledge during my study period. May God bless you.

I also would like to convey my gratitude to my co-supervisors, Professor Gan Siew Hua, Assoc Professor Dr Md Salzihan Md Salleh and Dr VMK Bhavaraju for their encouragement, kind supervision and assistance during this study. My sincere thanks also goes to the co-researches in this study, Assoc.Prof Dr Andee Dzulkarnaen Zakaria, Dr Maya Mazuwin Yahaya, Dr Ibtisam Mohamad and also Professor Dr Norsa'adah Bachok and Dr Ismail Ibrahim for their help in statistical analysis. Also i would like to the HUSM staff, Pn Roziatun Bt Mohd Ghani, Pn Jamaliah Lin and Engku Syera for their contribution and assistance in TNBC patients recruitment and sample collection.

I also would like to acknowledge Assoc. Prof Dr Sarina Sulong, Director of Human Genome Centre and lecturers, Dr Nazihah Yunus, Dr Tan Huay Lin for their valuable discussion on laboratory works, skills and knowledge in area of study. This study was supported partially by Research University (Team) (RUT) (1001/PPSP/853005) grant of Universiti Sains Malaysia. I am also deeply indebted to School of Medical Sciences (especially Human Genome Centre) for providing all the research facilities in order to complete this study. I am also grateful to the Ministry of Education for awarding me the MyBrain 15-My Phd scholarship from 2014-2017. Many thanks to Human Genome Centre staff Mr Mohd Ros, Ms Nor Atifah, Mr Chia, Ms Siti Mariam, Ms Alia, Ms Hidayah, Mr Nik, Mr Qais, Mr Zaki, Ms Hafizah, Pn Zulaikha, Ms Asraihan, Cik Faten and HGC students, Dr Murtala, Dr Aziati, Dr Fatimah, Dr Eva, Dr Rose, Dr Tan Shing Cheng, Najlaa, Maziras, Kak Yati, Kak Sha, Sathiya, Roslina, Sabrina, Fazreen, Syidah, Ninie, Sarifah, Ameirah, Pei and other students for their continuous supports, stimulating discussion and knowledge throughout my study period.

I would to express my special thanks to my father Abdul Aziz B Ab Ghani, my mother, Noriah Bt Omar, my wife (Ms Ashuvila), my daughter (Nur Iman Damia'), my siblings (Nur Izzati, Ahmad Faris, Ahmad Firdaus and Nur Ainun) as well as my friends for their understanding and being supportive and encouraging throughout my study.

Finally, I would like to thank every person (if I had left out to name) who had contributed and involved in this study.

-Ahmad Aizat B Abdul Aziz-

TABLE OF CONTENTS

Acknowledgements	ii
Table of Contents	iv
List of Tables	xiv
List of Figures	xviii
List of Appendices	xxiii
List of Abbreviations	xxiv
Abstrak	xxxi
Abstract	xxxiii

CHA	CHAPTER 1 INTRODUCTION		1
1.1	Breast	cancer	1
1.2	The in	cidence and prevalenve of breast cancer	2
1.3	Breast	cancer subtypes	3
1.4	Breast	cancer risk factors	3
1.5	Screen	ing and diagnosis of breast cancer	6
1.6	Histological staging and grading		7
1.7	Management and treatment of breast cancer		10
1.8	Breast cancer prevention		12
1.9	Presen	t study: Problem statement	13
	1.9.1	Genetic determinants of variable chemotherapy response	15
		and recurrence risk	
	1.9.2	Objective(s) of the study	20
	1.9.3	Hypothesis	21

CHA	PTER 2	LITERAT	URE REVIE	W			22
2.1	Triple negative breast cancer (TNBC)				22		
	2.1.1	Incidence	e of TNBC				23
	2.1.2	Risk fact	ors associated	l with TNBC			24
	2.1.3	Molecula	ar, histologica	l subtypes and	l clinical prese	ntation	26
		of TNBC	2				
	2.1.4	Treatmer	nt for TNBC				27
2.2	Adjuva	ant che	motherapy:	docetaxel,	doxorubicin	and	28
	cyclop	hosphamid	le (TAC) regin	nen			
2.3	Drug re	esistance					30
2.4	Cytoch	rome P450) enzymes (C	YPs)			37
	2.4.1	Cytochro	ome P450 fam	ily 1 subfamily	y B member 1		38
		2.4.1(a)	CYP1B1	polymorphis	ms and	their	39
			associationw	ith drug respo	nse/resistance		
		2.4.1(b)	CYP1B1 mF	RNA expressio	on and its asso	ciation	41
			with drug rea	sponse/resistan	ice		
	2.4.2	Cytochro	ome P450 (CY	P) family 3 su	bfamily A (CY	TP3A)	42
		2.4.2(a)	CYP3A4 and	d CYP3A5 pol	ymorphisms an	d their	43
			association v	with drug respo	onse/resistance		
		2.4.2(b)	CYP3A4 and	d CYP3A5 m	RNA expression	on and	45
			association v	with drug respo	onse/resistance		
2.5	Adenos	sine tripho	sphate (ATP)	binding casset	te (ABC) subfa	mily B	48

member 1 (ABCB1)

2.3.1	ABCB1 polymorphisms and their association with drug	48
	response/resistance	
2.5.2	ABCB1 mRNA expression and its association with	51
	treatment response	
MicroR	NA (miRNA)	52
2.6.1	miR-21	54
2.6.2	miR-27b	57
2.6.3	miR-34a	58
2.6.4	miR-182	60
2.6.5	miR-200c	61
2.6.6	miR-451	62
PTER 3	MATERIALS AND METHODS	64
Study d	lesign	64
Sample	size calculation	64
Patients recruitment 6		
Collect	ion of pathological data and evaluation of treatment response	66
Sample	collection	68
Genetic	e association study	68
3.6.1	Genomic DNA extraction	68
3.6.2	DNA concentration and quality	69
3.6.3	Single nucleotide polymorphisms (SNPs) genotyping	70
	3.6.3(a) Allele specific PCR (AS-PCR)	73
	3.6.3(a) Allele specific PCR (AS-PCR)3.6.3(b) Restriction Fragment Length Polymorphism	73 73
	2.5.2 MicroR 2.6.1 2.6.2 2.6.3 2.6.4 2.6.5 2.6.6 2.6.6 2.6.6 2.6.6 2.6.6 2.6.6 2.6.6 2.6.6 2.6.6 2.6.6 2.6.6 2.6.1 3.6.1 3.6.2	response/resistance 2.5.2 ABCB1 mRNA expression and its association with treatment response MicroRNA (miRNA) 2.6.1 miR-21 2.6.2 miR-34a 2.6.3 miR-34a 2.6.4 miR-182 2.6.5 miR-200c 2.6.6 miR-451 PTER 3 MATERIALS AND METHODS Study design Study design Collection of pathological data and evaluation of treatment response Sample collection Genetic association study 3.6.1 Genomic DNA extraction 3.6.2 DNA concentration and quality

3.7	Agarose gel preparati	on	74
3.8	Gel electrophoresis pr	rotocol	76
3.9	PCR product purificat	tion and DNA sequencing	76
3.10	mRNA and miRNA e	expression levels	77
	3.10.1 Total RNA ex	xtraction	77
	3.10.2 Total RNA ex	xtraction concentration and quality	79
	3.10.3 cDNA synthe	esis	79
	3.10.4 Pre-amplifica	ation of cDNA	80
	3.10.5 Quantitative	reverse transcription polymerase chain	82
	reaction (ql	RT-PCR)	
	3.10.6 mRNA expre	ession analysis of CYP1B1, CYP3A4, CYP3A5	83
	and ABCB1		
	3.10.7 miRNA RT-I	PCR	84
	3.10.8 miRNA pre-a	amplification PCR	85
	3.10.9 miRNA qRT	-PCR	87
3.11	Statistical analysis		88
CHAI	PTER 4 RESULTS		90
4.1	Characteristics of stud	dy subjects	90
4.2	Results for AS-PCR a	and PCR-RFLP analysis	91
	4.2.1 Visualization	n of AS-PCR of CYP1B1 142 C>G	92
	polymorphism	m	
	4.2.2 Visualization	n of PCR-RFLP of CYP1B1 4326 C>G	93
	polymorphisi	m	

- 4.2.3 Visualization of PCR-RFLP of *CYP1B1* 4390 A>G 94 polymorphism
- 4.2.4 Visualization of PCR-RFLP of *CYP3A4* 878 T>C 95 polymorphism
- 4.2.5 Visualization of PCR-RFLP of *CYP3A5* 6986A>G 96 polymorphism
- 4.2.6 Visualization of PCR-RFLP of *ABCB1* 1236 C>T 97 polymorphism
- 4.2.7 Visualization of PCR-RFLP of *ABCB1* 2677 G>T/A 98 polymorphism
- 4.2.8 Visualization of PCR-RFLP of *ABCB1* 3435 C>T 99 polymorphism
- 4.3 Genotype and allele frequencies of investigated polymorphisms in 100 chemotherapy response and chemoresistant groups of TNBC patients
 - 4.3.1 Genotype and allele frequencies of *CYP1B1* 142 C>G, 4326 100
 C>G and 4390 A>G polymorphisms in chemotherapy response and chemoresistant groups of TNBC patients
 - 4.3.2 Genotype and allele frequencies of *CYP3A4* 878 T>C and 103*CYP3A5* 6986 A>G polymorphisms in chemotherapy response and chemoresistant groups of TNBC patients
 - 4.3.3 Genotype and allele frequencies of *ABCB1* 1236 C>T, 2677 105
 G>T and 3435 C>T polymorphisms in chemotherapy response and chemoresistant groups of TNBC patients
- 4.4 Association of the SNPs with chemotherapy response 108

	4.4.1	Association of CYP1B1 142 C>G, 4326 C>G and 4390	108
		A>G polymorphisms with chemotherapy response	
	4.4.2	Association of CYP3A4 878 T>C and CYP3A5 6986 A>G	111
		polymorphisms with chemotherapy response	
	4.4.3	Association of <i>ABCB1</i> 1236 C>T, 2677 G>T and 3435 C>T	113
		polymorphisms with chemotherapy resistance	
	4.4.4	Association of 21 combination polymorphic genotypes with	115
		chemotherapy response	
4.5	LD and	d haplotype analysis	127
	4.5.1	Haplotype frequencies in chemoresistant and	128
		chemoresponse groups	
	4.5.2	Association of haplotypes with chemotherapy response	128
4.6	Analys	sis of gene expressions in cancerous and normal adjacent	131
	tissues	of triple negative breast cancer patients	
	4.6.1	Clinicopathological data of TNBC tissues	131
	4.6.2	CYP1B1, CYP3A4, CYP3A5 and ABCB1 mRNA expression	132
		analysis	
	4.6.3	Relative expression of CYP1B1, CYP3A4, CYP3A5 and	134
		ABCB1 in cancerous versus normal adjacent tissues	
	4.6.4	Relative expression level of CYP1B1 with	135
		clinicopathological parameters	
	4.6.5	Relative expression level of ABCB1 with	135
		clinicopathological parameters	
	4.6.6	Difference in relative expression of CYP1B1 and ABCB1 in	138
		cancerous tissues based on clinicopathological variables	

- 4.6.7 Relative expression level of *CYP1B1* and *ABCB1* in 138 chemoresistant versus chemoresponder groups
- 4.6.8 Relationship between genetic polymorphisms and gene 141 expression levels
- 4.7 miRNAs expression analysis 142
 - 4.7.1 The relative miRNAs expression in cancerous and normal 143 adjacent tissues of triple negative breast cancer patients
 - 4.7.2 The relative expression levels of candidate miRNAs in 144 cancerous versus normal adjacent tissues of different histological subtypes
 - 4.7.3 The relative expression levels of miRNAs in cancerous 144 versus normal adjacent tissues of patients with different stages of TNBC
 - 4.7.4 The relative expression levels of miRNAs in cancerous 147 versus normal adjacent tissues of TNBC patients with different histology grading
 - 4.7.5 The relative expression levels of the miRNAs in cancerous 147 versus normal adjacent tissues of premenopausal and postmenopausal TNBC patients
 - 4.7.6 The relative expression levels of miRNAs in cancerous 150 versus normal adjacent tissues based on lymph node metastasis
 - 4.7.7 Relative expression levels of miRNAs among different 152 clinicopathological variables

Х

	4.7.8	The relative expression of miRNAs in chemotherapy	155
		resistant versus chemoresponder groups	
4.8	Surviva	al analysis: Patient demographic details, polymorphism,	156
	clinico	pathological variables on relape-free survival (RFS) and	
	overall	survival (OS) of TNBC patients	
	4.8.1	RFS of TNBC patients	156
	4.8.2	OS of TNBC patients	177
CHAI	PTER 5	DICUSSION	196
5.1	Age, in	cidence and clinicopathological data of TNBC patients	196
5.2	PCR-R	FLP and AS-PCR methods	199
5.3	Genetic	c variation and chemotherapy response	200
	5.3.1	CYP1B1 polymorphisms and chemotherapy response	201
	5.3.2	CYP3A4 and CYP3A5 polymorphisms and chemotherapy	205
		response	
	5.3.3	ABCB1 polymorphisms and chemotherapy response	209
	5.3.4	Genotype combination of the polymorphisms and	214
		association with treatment response	
5.4	LD and	l haplotype analysis	215
	5.4.1	LD and haplotype analysis of CYP1B1	216
	5.4.2	LD and haplotype analysis of CYP3A4 and CYP3A5	217
	5.4.3	LD and haplotype analysis of ABCB1	218
5.5	Expres	sion analysis	220
	5.5.1	Techniques used: Total RNA extraction from FFPE	220
		samples	

	5.5.2	qRT-PCR method	222
	5.5.3	mRNA expression	223
		5.5.3(a) CYP1B1 mRNA expression and treatment	225
		response	
		5.5.3(b) <i>CYP3A4</i> and <i>CYP3A5</i> mRNA expressions	227
		5.5.3(c) ABCB1 mRNA expression and treatment	229
		response	
	5.5.4	Influence of genetic variations on gene expression	232
5.6	miRNA	A expression	234
	5.6.1	miR-21 and chemotherapy response	235
	5.6.2	miR-27b and chemotherapy response	238
	5.6.3	miR-34a and chemotherapy response	240
	5.6.4	miR-182 and chemotherapy response	243
	5.6.5	miR-200c and chemotherapy response	245
	5.6.6	miR-451 and chemotherapy response	247
5.7	Surviva	al analysis based on clinicopathological variables, candidate	250
	polymo	orphisms, mRNA and miRNA expression levels in TNBC	
	patients	s	
	5.7.1	Association between clinicopathological variables and RFS	251
		and OS in TNBC patients	
	5.7.2	Association between genetic polymorphisms and RFS and	252
		OS	
	5.7.3	Association of mRNA and miRNA expression levels with	255
		RFS and OS in TNBC patients	

CHAI	CHAPTER 6 SUMMARY AND CONCLUSION			
6.1	Summary of findings	263		
6.2	Limitations of the present study	266		
6.3	Strengths and novelty of the study	268		
6.4	Future recommendations	269		
6.5	Conclusion	272		
REFE	ERENCES	273		
APPENDICES				
LIST OF PRESENTATIONS				
LIST	LIST OF PUBLICATIONS			

LIST OF AWARDS RECEIVED

LIST OF TABLES

Page

Table 1.1	American Joint Commission on Cancer (7 th Edition, 2009)	8
	guidelines-tumour node metastasis (TNM) classification	
Table 1.2	Clinical staging- American Joint Commission on Cancer	9
	(7 th Edition, 2009) guidelines	
Table 3.1	Composition of PCR mixture	71
Table 3.2	PCR conditions for genotyping of the selected SNPs	71
Table 3.3	List of primer sequences and amplicon sizes	72
Table 3.4	Composition of RFLP reaction mixture	74
Table 3.5	List of restriction enzymes, incubation temperatures, time	75
	and expected band sizes in RFLP analysis	
Table 3.6	Composition of reaction mixture for reverse transcription	80
	of total RNA	
Table 3.7	ABI inventoried Taqman ® gene expression assays	81
Table 3.8	Composition of pre-amplification reaction mixture	81
Table 3.9	cDNA pre-amplification PCR conditions	82
Table 3.10	Composition of qRT-PCR reaction mixture	84
Table 3.11	qRT-PCR thermal cycling conditions	84
Table 3.12	ABI inventoried Taqman® miRNA expression assays	85
Table 3.13	Composition of miRNA RT-PCR reaction mixture	86
Table 3.14	Composition of miRNA pre-amplification reaction	86
	mixture	
Table 3.15	miRNA pre-amplification thermal cycling conditions	86
Table 3.16	Composition of miRNA qRT-PCR reaction mixture	87

Table 3.17	miRNA qRT-PO	CR thermal cycling conditions	88
------------	--------------	-------------------------------	----

- Table 4.1Clinicopathological data of TNBC patients90
- Table 4.2Genotype and allele frequency of CYP1B1 142 C>G, 4326102C>G and 4390 A>G polymorphisms in chemotherapy
resistant and chemoresponder groups of TNBC patients
- Table 4.3Genotype and allele frequency of CYP3A4 878 T>C and104CYP3A56986A>Gpolymorphisms in chemotherapyresponse and chemoresistant groups of TNBC patients
- Table 4.4Genotype and allele frequency of ABCB1 1236 C>T,1072677G>T and 3435 C>T polymorphisms in chemotherapyresponse and chemoresistant groups of TNBC patients
- Table 4.5Genetic association of CYP1B1 polymorphisms with110chemotherapy response
- Table 4.6Genetic association of CYP3A4 878 T>C and CYP3A51126986 A>G polymorphisms with chemotherapy response
- Table 4.7Genetic association of ABCB1 1236 C>T, ABCB1 2677114G>Tand ABCB1 3435C>Tpolymorphisms withchemotherapy response
- Table 4.8Association of 21 combinations of the investigated116polymorphisms with chemotherapy response
- Table 4.9Haplotype frequencies in chemotherapy resistant and129chemoresponse groups of TNBC patients
- Table 4.10Association of investigated haplotypes with chemotherapy130response in TNBC patients
- Table 4.11Clinicopathological data of TNBC tissues131

- Table 4.12The PCR efficiency, slope and correlation for mRNA133expression
- Table 4.13The number of Ct value (40 cycles) detected in cancerous133and normal adjacent tissues of TNBC patients
- Table 4.14
 Relative expression of CYP1B1 and association with
 136

 clinicopathological parameters
 136
- Table 4.15The relative expression of ABCB1 and their association137with the clinicopathological parameters
- Table 4.16Relative expression of CYP1B1 and ABCB1 in cancerous139tissues on clinicopathological variables
- Table 4.17Relationship between genetic polymorphisms and gene141expression levels
- Table 4.18The PCR efficiency, slope and correlation for miRNA142expressions
- Table 4.19Relative expression level ratio of the miRNAs in cancerous145versus normal adjacent tissues based on differenthistological subtypes
- Table 4.20Relative expression levels of miRNAs in cancerous versus146normal adjacent tissues at different stages
- Table 4.21Relative expression levels of the miRNAs in cancerous vs.148normal adjacent tissues of TNBC patients with differenthistological grading
- Table 4.22Relative expression levels of the miRNAs in cancerous vs.149normaladjacenttissuesofpostmenopausalTNBC patients

- Table 4.23Relative expression levels of miRNAs in cancerous vs.151normal adjacent tissues of patients with axillary lymphnode metastasis
- Table 4.24Relative expression level of miRNAs among different153clinicopathological variables
- Table 4.25Univariate analysis on clinicopathological variables and171SNPs of TNBC patients and risk of relapse
- Table 4.26Univariate Cox analysis on mRNA and miRNA expression174levels of TNBC patients and risk of relapse
- Table 4.27Multivariate Cox analysis on clinicopathological variables175and genetic variables of TNBC patients and risk of relapse
- Table 4.28Univariate analysis on clinicopathological variables and191SNPs of TNBC patients and risk of death
- Table 4.29Univariate Cox analysis on mRNA and miRNA expression194levels of TNBC patients and risk of death
- Table 4.30Multivariate Cox analysis of TNBC patients and risk of195death

LIST OF FIGURES

Page

Figure 2.1	Similarities of TNBC, BLBC and BRCA-1 breast cancer			
Figure 2.2	Six mechanisms involved in TNBC chemoresistance			
Figure 3.1	Flow chart of the study design	67		
Figure 4.1	Gel picture showing AS-PCR amplicons of CYP1B1 142	92		
	C>G polymorphism			
Figure 4.2	Gel picture showing different genotype patterns of	93		
	CYP1B1 4326 C>G polymorphism			
Figure 4.3	Gel picture showing the homozygous wildtype genotype	94		
	of CYP1B1 4390 A>G polymorphism			
Figure 4.4	Gel picture showing different genotype patterns of	95		
	<i>CYP3A4</i> 878 T>C polymorphism			
Figure 4.5	Gel picture showing different genotype patterns of	96		
	CYP3A5 6986 A>G polymorphism			
Figure 4.6	Gel picture showing different genotype patterns of	97		
	ABCB1 1236 C>T polymorphism			
Figure 4.7a	Gel picture showing different genotype patterns of	98		
	ABCB1 2677 G>T polymorphism			
Figure 4.7b	Gel picture showing different genotype patterns of	98		
	ABCB1 2677 G>A polymorphism			
Figure 4.8	Gel picture showing different genotype patterns of	99		
	ABCB1 3435 C>T polymorphism			
Figure 4.9	LD blocks of 8 investigated SNPs	127		

- Figure 4.10 Box plot showing relative expression of *CYP1B1*, 134 *CYP3A4*, *CYP3A5* and *ABCB1* in cancerous versus normal adjacent tissues.
- Figure 4.11 Box plot showing the relative expression levels of 140 *CYP1B1* and *ABCB1* with chemotherapy response
- Figure 4.12 Box plot showing the relative expression of miRNA 143 levels in cancerous and normal adjacent tissues
- Figure 4.13 Box plot showing the relative expression of miRNAs in 155 chemoresistant versus chemoresponder group of TNBC patients
- Figure 4.14 5-year cumulative RFS analysis of TNBC patients using 158 Kaplan-Meier survival analysis
- Figure 4.15 Kaplan Meier curve of RFS probability of TNBC patients 158 according to age groups
- Figure 4.16 Kaplan Meier curve of RFS probability of TNBC patients 159 according to histology types
- Figure 4.17 Kaplan Meier curve of RFS probability of TNBC patients 159 according to tumour histograde
- Figure 4.18 Kaplan Meier curve of RFS probability of TNBC patients 160 according to tumour stage
- Figure 4.19 Kaplan Meier curve of RFS probability of TNBC patients 160 according to axillary lymph node metastasis
- Figure 4.20 Kaplan Meier curve of RFS to menopausal status 161
- Figure 4.21 Kaplan Meier curve of RFS probability of TNBC patients 161 according to *CYP1B1* 142 C>G polymorphism

- Figure 4.22 Kaplan Meier curve of RFS probability of TNBC patients 162 according to *CYP1B1* 4326 C>G polymorphism
- Figure 4.23 Kaplan Meier curve of RFS probability of TNBC patients 162 according to *CYP3A4* 878 T>C polymorphism
- Figure 4.24 Kaplan Meier curve of RFS probability of TNBC patients 163 according to *CYP3A5* 6986 A>G polymorphism
- Figure 4.25Kaplan Meier curve of RFS probability of TNBC patients163according to ABCB11236 C>T polymorphism
- Figure 4.26 Kaplan Meier curve of RFS probability of TNBC patients 164 according to *ABCB1* 2677 G>T polymorphism
- Figure 4.27 Kaplan Meier curve of RFS probability of TNBC patients 164 according to *ABCB1* 3435 C>T polymorphism
- Figure 4.28 Kaplan Meier curve of RFS probability of TNBC patients 165 according to *CYP1B1* expression level
- Figure 4.29 Kaplan Meier curve of RFS probability of TNBC patients 165 according to *ABCB1* expression level
- Figure 4.30 Kaplan Meier curve of RFS probability of TNBC patients 166 according to miR-21 expression level
- Figure 4.31 Kaplan Meier curve of RFS probability of TNBC patients 166 according to miR-27b expression level
- Figure 4.32 Kaplan Meier curve of RFS probability of TNBC patients 167 according to miR-34a expression level
- Figure 4.33 Kaplan Meier curve of RFS probability of TNBC patients 167 according to miR-182 expression level

- Figure 4.34 Kaplan Meier curve of RFS probability of TNBC patients 168 according to miR-200c expression level
- Figure 4.35 Kaplan Meier curve of RFS probability of TNBC patients 168 according to miR-451 expression level
- Figure 4.36 5-year cumulative OS of TNBC patients using Kaplan- 179 Meier survival analysis
- Figure 4.37 Kaplan Meier curve of OS probability of TNBC patients 179 according to age groups
- Figure 4.38 Kaplan Meier curve of OS probability of TNBC patients 180 according to histology types
- Figure 4.39 Kaplan Meier curve of OS probability of TNBC patients 180 according to histology grade
- Figure 4.40 Kaplan Meier curve of OS probability of TNBC patients 181 according to tumour staging
- Figure 4.42 Kaplan Meier curve of OS probability of TNBC patients 181 according to axillary lymph node metastasis
- Figure 4.42 Kaplan Meier curve of OS probability of TNBC patients 182 according to menopausal status
- Figure 4.43 Kaplan Meier curve of OS probability of TNBC patients 182 according to *CYP1B1* 142 C>G polymorphism
- Figure 4.44 Kaplan Meier curve of OS probability of TNBC patients 183 according to *CYP1B1* 4326 C>G polymorphism
- Figure 4.45 Kaplan Meier curve of OS probability of TNBC patients 183 according to *CYP3A4* 878 T>C polymorphism

- Figure 4.46 Kaplan Meier curve of OS probability of TNBC patients 184 according to *CYP3A5* 6986 A>G polymorphism
- Figure 4.47 Kaplan Meier curve of OS probability of TNBC patients 184 according to *ABCB1* 1236 C>T polymorphism
- Figure 4.48 Kaplan Meier curve of OS probability of TNBC patients 185 according to *ABCB1* 2677 G>T polymorphism
- Figure 4.49 Kaplan Meier curve of OS probability of TNBC patients 185 according to *ABCB1* 3435 C>T polymorphism
- Figure 4.50 Kaplan Meier curve of OS probability of TNBC patients 186 according to *CYP1B1* expression level
- Figure 4.51 Kaplan Meier curve of OS probability of TNBC patients 186 according to *ABCB1* expression level
- Figure 4.52 Kaplan Meier curve of OS probability of TNBC patients 187 according to miR-21 expression level
- Figure 4.53 Kaplan Meier curve of OS probability of TNBC patients 187 according to miR-27b expression level
- Figure 4.54 Kaplan Meier curve of OS probability of TNBC patients 188 according to miR-34a expression level
- Figure 4.55 Kaplan Meier curve of OS probability of TNBC patients 188 according to miR-182 expression level
- Figure 4.56 Kaplan Meier curve of OS probability of TNBC patients 189 according to miR-200c expression level
- Figure 4.57 Kaplan Meier curve of OS probability of TNBC patients 189 according to miR-451 expression level

LIST OF APPENDICES

- APPENDIX A Ethical Approval From Hospital USM
- APPENDIX B Ethical Approval From NMRR
- APPENDIX C Patients Information and Consent Form
- APPENDIX D Polymorphic Genotype of the Study Subjects
- APPENDIX E Clinicopathological Variables of Study Subjects
- APPENDIX F Research Questionaire
- APPENDIX G DNA sequencing results

LIST OF ABBREVIATIONS

°C	'Degree Celcius'
%	Percent
μL	Microlitre
μΜ	Micromolar
5-FU	5-Fluorouracil
A260/230	Absorbance At 260 Nm And 230 Nm
A260/280	Absorbance At 260 Nm And 280 Nm
ABC	ATP-Binding Cassette
ABCB1	ATP-Binding Cassette Subfamily B Member 1
AC	Adriamycin And Cyclophosphamide
AC-T	Adriamycin, Cyclophosphamide, Taxane
ADR	Adriamycin
AE	Elution Buffer
AhRR	Aryl Hydrocarbon Receptor Repressor
AKT	Protein Kinase B
AL	Lysis Buffer
AP-1	Activator Protein 1
ARNT	Aryl Receptor Nuclear Translocator
AS-PCR	Allele Specific-Polymerase Chain Reaction
ATP	Adenosine Triphosphate
AUC	Area Under Curve
AW1	Washing Buffer 1
AW2	Washing Buffer 2

BCl2	B-Cell Lymphoma 2
BLAST	Basic Local Alignment Search Tool
BLBC	Basal Like Breast Cancer
BMI	Body Mass Index
BmiI	Polycomb Complex Protein
bp	Base Pair
BRCA 1	Breast Cancer Gene 1
BRCA 2	Breast Cancer Gene 2
CAF	Cyclophosphamide, Adriamycin and Fluorouracil
CBLB	E3 Ubiquitin-Protein Ligase
CCND1	Cyclin-D1
CCNG1	Cyclin-G1
CDK6	Cell Division Protein Kinase 6
cDNA	Complementary Deoxyribonucleic Acid
CIs	Confidence Intervals
CMF	Cyclophosphamide, Methotrexate, and Fluorouracil
COX	Cyclooxygenase
COX-1	Cyclooxygenase-2
CREB1	Camp Responsive Element Binding Protein 1
Ct	Cycle Threshold
CT scan	Computed Tomography scan
CYP1B1	Cytochrome P450 Family 1 Subfamily B Member 1
CYP3A4	Cytochrome P450 Family 3 Subfamily A Member 4
CYP3A5	Cytochrome P450 Family 3 Subfamily A Member 5
CYPs	Cytochrome P450

D'	Coefficient of Linkage Disequilibrium			
DCIS	Ductal Carcinoma In Situ			
DFS	Disease-Free Survival			
DNA	Deoxyribonucleic Acid			
dNTPs	Deoxyribonucleotide Triphosphate			
DOX	Doxorubicin			
DPD	Dihydropyrimidine Dehydrogenase			
EB	Elution Buffer			
EDTA	Ethylenediaminetetraacetic Acid			
EMT	Epithelial-Mesenchymal Transition			
ENPP1	Ectonucleotide Pyrophosphatase/Phosphodiesterase 1			
ER	Oestrogen receptor			
FAS-L	First Apoptosis Signal Ligand			
FB-XW7	F-Box And WD Repeat Domain-Cointaning 7			
FEC	Fluorouracil (5FU), Epirubicin And Cyclophosphamide			
FFPE	Formalin-Fixed Paraffin Embedded			
FOX1	Forkhead Box 1			
FOXF2	Forkhead Box F2			
FOXO1	Forkhead Box Protein O1			
FOXO3	Forkhead Box O3			
FRA17B	Fragile Site, Aphidicolin Type, Common, Fra(17)(Q23.1)			
g	Gram			
GAPDH	Glyceraldehyde 3-Phosphate Dehydrogenase			
GRB2	Growth Factor Receptor-Bound Protein 2			
HER2	Human Epidermal Growth Receptor Factor-2			

HOTAIR	Hox Antisense Intergenic RNA
HR	Hazard Ratio
HSF2	Heat Shock Transcription Factor 2
HVP16	Human Papillomavirus 16
IDC-NOS	Invasive Ductal Carcinoma-No Otherwise Specified
JFCR	Japanese Foundation of Cancer Research
kb	Kilobase
LD	Linkage Disequilibrium
mA	Milliampere
MDR	Multidrug Resistance
MgCl ₂	Magnesium Chloride
MIM	Missing In Metastasis
miRNAs	MicroRNAs
MITF	Melanogenesis Associated Transcription Factor
mL	Millilitre
MLH1	MutL protein homolog 1
mM	Millimolar
MMIF	Macrophage Migration Inhibitory Factor
MREC	Medical Research and Ethics Committee
MRI	Magnetic Resonance Imaging
mRNAs	Messenger RNAs
MSH2	MutS protein homolog 2
MSI	Microsatellite Instability
MTSS1	Metastasis Suppressor 1
NC1	National Cancer Institute

NF-κB	Nuclear Factor-Kappa B
ng	Nanogram
NOTCH1	Notch Homolog 1
NR5A2	Nuclear Receptor Subfamily 5, Group A, Member 2
NW	Washing buffer
OR	Odds Ratio
OS	Overall Survival
PARP1	Poly-ADP Ribose Polymerase 1
PB	Binding buffer
pCR	Pathological Complete Response
PCR	Polymerase Chain Reaction
DCD DEI D	Polymerase Chain Reaction- Restriction Fragment Length
r CK-KI ⁻ LF	Polymorphism
PDCD4	Programmed Cell Death 4
P-gp	Permeability-Glycoprotein
PR	Progesterone receptor
PRC2	Polycomb Repressive Complex 2
PRKD1	Protein Kinase D1
PTEN	Phosphatase And Tensin Homolog
qRT-PCR	Quantitative Reverse Transcription-Polymerase Chain Reaction
r^2	Coefficient of Determination
RAB14	Ras-Related Protein
RECK	Reversion Inducing Cysteine Rich Protein With Kazal Motifs
REST	Relative Expression Software Tools
RFS	Relape-Free Survival

RIN **RNA** Integrity Number RNA **Ribonucleic Acid Revolutions Per Minute** rpm SD Standard Deviation SE Standard Error **SNPs** Single Nucleotide Polymorphisms SPSS Statistical Package For The Social Sciences TAC Taxane, Adriamycin, Cyclophosphamide TBE Tris-Boric Acid EDTA TCGA The Cancer Genome Atlas ΤE Tris EDTA TGF-β1 Transforming Growth Factor Beta 1 TIMP1 Timp Metallopeptidase Inhibitor 1 TMEM49 **Transmembrane Protein-49** TNBC Triple Negative Breast Cancer TNM Tumour-Node-Metastasis TPM1 Tropomyosin 1 TrKB Tropomyosin Receptor Kinase B TSS **Transcription Start Site** TUBB3 Tubulin Beta 3 Class III U Unit UTR Untranslated Region Ultra Violet UV V Voltage Vascular Endothelial Growth Factor- A VEGF-A

YWHAZ	Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase
	Activation Protein Zeta
ZEB1	Zinc Finger E-Box Binding Homeobox 1
ZEB2	Zinc Finger E-Box Binding Homeobox 2

PENENTU GENETIK DALAM TINDAK BALAS TAC KEMOTERAPI DALAM PESAKIT KANSER PAYUDARA TIGA KALI NEGATIF

ABSTRAK

Kanser payudara tiga kali negatif (TNBC), salah satu subtip dalam kanser payudara yang dikategorikan sebagai fenotip yang agresif, kadar ulangan yang tinggi dan prognosis yang buruk dan merupakan cabaran klinikal yang penting kerana kekurangan terapi yang khusus. Walaupun, pesakit TNBC dirawat dengan regimen kemoterapi taxane, adriamycin dan cyclophosphamide (TAC), kerintangan ubatan dan pertumbuhan tumor ulangan adalah halangan utama dalam rawatan TNBC. Penanda prognostik bagi TNBC masih sukar difahami. Kajian ini dijalankan untuk menyelidik kesan SNP yang dipilih CYP1B1 142 C> G (rs10012), 4326 C> G (rs1056836) dan 4390 A> G (rs1800440), CYP3A4 878 T> C (rs28371759), CYP3A5 6986 A > G (rs776746), ABCB1 1236 C>T (rs1128503), 2677 G>T / A (rs2032582) dan 3435 C> T (rs1045642) dan ekspresi gen serta tahap ekspresi miRNA yang dipilih (miR-21, miR-27b, miR-34a, miR-182, miR-200c dan miR-451) dalam memodulasi tindak balas kemoterapi TAC serta hasil rawatan pada pesakit TNBC. Tujuh puluh enam (76) sampel darah and 41 tisu blok FFPE dari pesakit yang sama disahkan secara klinikal dan histopatologi pesakit TNBC. DNA (sample darah) dan keseluruhan RNA (tisu blok FFPE) diekstrak. Pengenotipan dilakukan menggunakan kaedah PCR-RFLP and AS-PCR seterusnya penjujukan DNA. Tahap ekspresi mRNA dan miRNA diukur dengan menggunakan kaedah qRT-PCR. Kesan terhadap rawatan dan penyakit dinilai setelah selesai kemoterapi. Berdasarkan respon kemoterapi, Pesakit dibahagikan kepada kerintangan kemoterapi dan respon kemoterapi. Dalam analisis perkaitan genetik, genotip homozigot dan alel mutasi CYP1B1 4326 C>G dan ABCB1 3435 C>T polimorfisme, gabungan genotip CYP1B1 142 GG + CYP3A4 878 TT dan CYP1B1 4326 GG + ABCB1 1236 CT dan haplotip CYP1B1 4326G / 142C, ABCB1 3435T / 2677G / 1236T dan ABCB1 3435T / 2677T / 1236T dikaitkan dengan risiko yang lebih tinggi untuk kerintangan kemoterapi. Manakala, genotip CYP1B1 142 CG secara signifikan dikaitkan dengan respon kemoterapi yang baik. Untuk analisis ekspresi mRNA dan miRNA, tahap ekspresi tinggi bagi CYP1B1 dikaitkan secara signifikan dengan kerintangan kemoterapi. Lebih-lebih lagi, regulasi yang tinggi bagi miR-21 dan miR-182 didapati berkaitan dengan peningkatan risiko pengulangan penyakit menjadi lebih teruk dan menjadi faktor prognosis dalam pesakit TNBC yang menjalani kemoterapi TAC. Sebaliknya, genotip CYP1B1 142 CG dijumpai sebagai faktor prognostik yang baik untuk meramalkan kelangsungan hidup dalam pesakit TNBC. Oleh itu, genotip CYP1B1 4326 GG, ABCB1 3435 TT, tahap regulasi CYP1B1 mRNA yang tinggi dan tahap regulasi miR-21 dan miR-182 yang tinggi menjadi penentu genetik terhadap tindak balas kemoterapi TAC didalam pesakit TNBC. Penentu genetik ini boleh dipertimbangkan sebagai penanda bio yang berpotensi yang mungkin akan membantu pegawai perubatan, terutamanya dalam risiko berulang dan / atau prognosis yang berulang dan seterusnya meningkatkan pengurusan pesakit TNBC.

GENETIC DETERMINANTS OF TAC CHEMOTHERAPY RESPONSE IN TRIPLE NEGATIVE BREAST CANCER PATIENTS

ABSTRACT

Triple negative breast cancer (TNBC), one of the breast cancer subtypes is characterised by aggresive phenotype, high rates of recurrence and poor prognosis and is an important clinical challenge due to lack of specific targeted therapy. Although, TNBC patients are treated with taxane, adriamycin and cyclophosphamide (TAC) chemotherapy regimen, drug resistance and tumour recurrence are major obstacles in TNBC treatment. Reliable prognostic marker of TNBC remains elusive. The present study was undertaken to investigate the impact of selected SNPs of CYP1B1 142 C>G (rs10012), 4326 C>G (rs1056836) and 4390 A>G (rs1800440), CYP3A4 878 T>C (rs28371759), CYP3A5 6986 A>G (rs776746), ABCB1 1236 C>T (rs1128503), 2677 G>T/A (rs2032582) and 3435 C>T (rs1045642) and their respective gene expressions as well as expression levels of selected miRNAs (miR-21, miR-27b, miR-34a, miR-182, miR-200c and miR-451) in modulating TAC chemotherapy response and treatment outcome in TNBC patients. Seventy six (76) blood samples and 41 match paired FFPE tissues blocks available from the same group of clinically and histopathologically confirmed TNBC patients, who had undergone surgery and completed six cycles of TAC chemotherapy regimen were included in the study. DNA (blood samples) and total RNA (FFPE tissues blocks) were extracted. Genotyping was carried out using PCR-RFLP and AS-PCR methods followed by DNA sequencing. mRNA and miRNA expression levels were determined using qRT-PCR. The treatment response and disease outcome of the patients were evaluated after completion of chemotherapy. Based on chemotherapy response, patients were

categorized into chemoresistant and chemoresponse groups. In genetic association analysis, homozygous variant genotype and variant allele of CYP1B1 4326 C>G and ABCB1 3435 C>T polymorphisms, combination of CYP1B1 142 GG + CYP3A4 878 TT and CYP1B1 4326 GG + ABCB1 1236 CT genotypes, CYP1B1 4326G/142C, ABCB1 3435T/2677G/1236T and ABCB1 3435T/2677T/1236T haplotypes were associated with significantly higher risk for chemoresistance. Whereas, CYP1B1 142 CG genotype was significantly associated with good chemoresponse. For mRNA and miRNA expression levels analysis, high expression level of CYP1B1 was significantly associated with chemoresistance. Moreover, up regulation of miR-21 and miR-182 were found to be associated with increased risk of relapse and to be a prognosis factor in TNBC patients undergoing TAC chemotherapy. On the other hand, CYP1B1 142 CG genotype was found to be a good prognostic factor for predicting survival in TNBC patients. Thus, CYP1B1 4326 GG, ABCB1 3435 TT genotypes, high CYP1B1 mRNA expression level and up regulation of miR-21 and miR-182 expression levels emerged as genetic determinants of TAC chemotherapy response in TNBC patients. These genetic determinants could be considered as potential biomarkers that might help the clinician, especially in predicitng recurrence risk and/or prognosis and thus improve management of TNBC patients.

CHAPTER 1

INTRODUCTION

1.1 Breast cancer

Breast cancer is a type of cancer that develops in the cell lining of milk ducts as well as the lobules that supply the duct with milk. Breast cancer develops from normal breast epithelial cells that evolve via atypical hyperplasia (and eventually dysplasia) to ductal carcinoma *in situ* (DCIS) and subsequently to invasive breast cancer. The process involves multiple molecular alterations involving genetic and epigenetic alterations in precursor and neoplastic cells, subsequently turning to metastatic breast cancer (Rivenbark *et al.*, 2013).

Generally, breast cancer can be divided into two (2) types; sporadic and hereditary forms. The most common form of breast cancer is the sporadic form which accounts for more than 85% of cases. Sporadic breast cancer results from genetic changes that occur only in breast cancer cells (somatic mutation) due to exposure or interaction with environmental factors. However, hereditary breast cancer which accounts for less than 15% of breast cancer cases, results from inherited germline mutations in high penetrant breast cancer susceptibility genes including breast cancer genes 1 and 2 (*BRCA1* and *BRCA2* genes) (Martin, 2001).

1.2 The incidence and prevalence of breast cancer

Breast cancer is a global health issue and is the commonest form of cancer and the leading cause of cancer-related deaths in women (Beiki *et al.*, 2012; Shah *et al.*, 2014). The incidence is increasing worldwide over the years with high mortality rate. More than one million new breast cancer cases were reported which accounts for 25% of all cancer types (Ferlay *et al.*, 2015).

According to Globocan, the standardized incidence rate of breast cancer was 43.1 per 100,000 population while the mortality rate was 12.9 per 100,000 population. The highest incidence was in Belgium (111.9 per 100,000), followed by Denmark (105 per 100,000), Bahamas (98 per 100,000) and Netherlands (96 per 100,000). Continent wise, the incidence rate was highest in Northern America (91.6 per 100,000), followed by Western Europe (91.1 per 100,000), Middle Africa (26.8 per 100,000) and Eastern Asia (27 per 100,000) respectively (Ghoncheh *et al.*, 2016a). Among South East Asian countries, Singapore had a higher incidence rate (65.7 per 100,000) followed by Brunei (48.6 per 100,000) and Philippines (47 per 100,000) (Youlden *et al.*, 2014).

According to the National Cancer Registry Malaysia report from 2007 to 2011, breast cancer was the commonest cancer type in women in Malaysia with a total of 18,343 (17.1%) cases reported followed by colorectal (13.2%) and lung (10.2%). Breast cancer accounts for 32.1% of all cancer in females with life time risk of 1 in 30 individuals and an age standardized rate of 31.1 per 100,000 in Malaysia (Azizah *et al.*, 2016).

1.3 Breast cancer subtypes

Breast cancer is a heterogenous malignancy and has many subtypes with different biological behaviour, clinic-pathological features and molecular characteristics (Yersal and Barutca, 2014). There are four major molecular subtypes of breast cancer; Oestrogen (ER) positive/luminal, Human epidermal growth receptor 2 (HER2) positive (HER2-enriched), basal-like and normal breast-like. However, recent study on the gene expression profiling revealed that breast cancer can be divided further into luminal A (ER positive and/or Progesterone (PR) positive, HER-2 negative), luminal B (ER positive and/or PR positive, HER-2 positive), HER-2 over expression (ER negative, PR negative, HER-2 positive) basal-like (ER negative, PR negative, HER-2 negative, HER-2 positive) basal-like (ER negative, PR negative, HER-1) positive, as well as normal breast-like (Boyle, 2012).

1.4 Breast cancer risk factors

Several epidemiological studies have shown that genetic and environmental or interactions between these two factors play an important role in increasing the risk of breast cancer. Factors such as age, breast pathology, family history and genetic predisposition as well as environmental factors have been reported as risk factors for breast cancer development. However, other factors such as exposure to endogenous and exogenous hormone such as oral contraceptive pills as well as life style related factors also contribute to increased risk of breast cancer development (Abdulkareem, 2013; Gotzsche and Jorgensen, 2013; Shah *et al.*, 2014).

Age, gender and personal history: The risk of developing breast cancer increases with age as well as being a female gender. Breast cancer is uncommon before age of 20 years. A study reported a rate of 10/100,000 for breast cancer in women aged below 25 years and the risk increased up to 100 times in women by the age 45 years (Dumitrescu and Cotarla, 2005). Women have been reported to have a higher risk for breast cancer development as compared to men. However, men who are shown to express ER, PR and androgen receptors as well as men with Klinefelter's syndrome have been reported to have a higher chance of breast cancer development (Murphy *et al.*, 2006). Personal history such as diagnosed DCIS, stage IIB and hormone receptor negative are shown to pose a higher risk of breast cancer (Buist *et al.*, 2010). So, also women who do not breast feed, pregnancy at early age, late menarche and early menopause are also reported to be at higher risk for breast cancer development (Collaborative Group on Hormonal Factors in Breast, 2002; Ritte *et al.*, 2012).

Breast pathology: Proliferative breast lesion without atypia, including usual ductal hyperplasia, intraductal papillomas, sclerosing adenosis and fibroadenomas may increase the risk of breast cancer development. Some studies showed that women with atypia had 4.3 folds higher risk of developing breast cancer as compared to a normal individual (Hartmann *et al.*, 2005; Shah *et al.*, 2014).

Family history: History of breast cancer in the family especially among first/second degree relatives is one of the most important risk factors for the development of breast cancer (Martin *et al.*, 2010a). Women with strong a family history of breast cancer may inherit some gene mutation that might influence the risk of breast cancer

development. In general, women with positive family history show early onset of breast cancer, bilateral breast cancer, advanced stage, positive lymph node, negative hormone receptors and a poorer prognosis (Verkooijen *et al.*, 2006). Genetic factor is the most important factor that contribute to familial breast cancer development. A study showed that, women with inherited mutations in genes such as *BRCA1*, *BRCA2*, *TP53*, *PTEN*, *STK1* had a higher risk for development of familial breast cancer (van der Groep *et al.*, 2011). In fact, women with inherited mutations in *BRCA1* had 40% to 85% lifetime risk of developing breast cancer and 25% to 65% for risk of developing ovarian cancer. On the other hand, those who have inherited *BRCA2* mutation pose similar risk of breast cancer, with an ovarian cancer risk estimated to be 15% to 20% (Pruthi *et al.*, 2010).

Lifestyle and habits: Due to modernization, lifestyle habits are changing. Several epidemiological studies have shown that lack of physical activities, alcohol consumption, tobacco smoking, high fat diet, obesity and high cholesterol may increase the risk of breast cancer development (Khan *et al.*, 2010). Alcohol consumption and tobacco smoking consist of various genotoxic agents such as reactive oxygen species (ROS), polycyclic aromatic hydrocarbon (PAH) and heterocyclic amines (HCA) that will lead to DNA damage in the cell. On the other hand, lack of physical activities and high fat diet increase the ER level in the body and thus increase the risk of breast cancer development and growth.

Endogenous and exogenous exposure: Women who are exposed to ionizing radiation (medical diagnostic or therapeutic) and environmental carcinogens may have

higher risk of breast cancer. In addition, hormone replacement therapy (HRT) and usage of oral contraceptives are reported to increase the risk of breast cancer (Abdulkareem, 2013; Dumitrescu and Cotarla, 2005). Contraceptives pill contain the female sex hormones such ER and progestogens. These hormones prevent pregnancy by stopping the ovaries releasing eggs (called ovulation). However, these hormones can increase the growth of some breast cancers, which might explain why taking the pill slightly increases the risk of breast cancer.

1.5 Screening and diagnosis of breast cancer

Breast self-examination (BSE) and clinical breast examination (CBE) are the first line screening processes for breast cancer detection. Most clinicians encourage women to perform BSE monthly. These techniques will help to detect early signs of breast cancer including the presence of lump in the breast, a change of breast shape, dimpling of the skin, nipple discharge or presence of red scaly patch of the skin. Besides that, bony pain, malaise and loss of weight are other general signs of breast cancer.

Advanced technique using automated machines such as mammography, ultrasound and magnetic resonance imaging are also being used in the screening and diagnosis of breast cancer. Mammography is an important technique in early detection of nonpalpable masses. However, routine mammography leads to undue stress and uncertainty in case of false positive results. Ultrasound helps clinician to screen breast cancers that could not be detected by mammography. However, MRI increase the modality in detection, assessment, staging and management of breast cancer (Shah *et al.*, 2014). In addition, mammogram, MRI scan, ultrasound and CT scan are also used to determine tumour growth and the metastatic spread to the lymph nodes, liver or other organs (Veronesi *et al.*, 2005). For diagnosis, tissue biopsies are taken followed by staining and observation under a microscope. Based on the findings, the tissues, if cancerous will be classified according to the Tumour (T), Nodes (N), Metastasis (M) (TNM) system (see section 1.7).

1.6 Histological staging and grading

In breast cancer staging and grading, TNM system is used based on the size of tumour (T) and whether tumour has spread to the lymph nodes or not (N) or whether the tumour has metastasized to other parts of the body (M). Following breast cancer diagnosis, the patients are clinically staged using the American Joint Commission on Cancer (AJCC) (7th Edition, 2009) guidelines, whereas tumour is histologically graded according to the Scaff Bloom and Richardson (SBR) histological system (Tables 1.1 and 1.2). Tumour grading compares breast cancer cells to the normal breast tissues and can be divided into three types; well differentiated (low grade), moderately differentiated (intermediate grade) and poorly differentiated (high grade) where the cells lose their features as compared to the normal breast cells.

Table 1.1: American Joint Commission on Cancer (7th Edition, 2009) guidelines -

tumour node metastasis (TNM) classification

Primary tumour	
(T)	
ТХ	Primary tumour cannot be assessed
T0	No evidence of primary tumour
Tis	Carcinoma in situ
Tis (DCIS)	Ductal carcinoma in situ
Tis (LCIS)	Lobular carcinoma in situ
Tis (Paget's)	Paget's disease of the nipple
T1	Tumour ≤ 20 mm in greatest dimension
T1mi	Tumour ≤ 1 mm in greatest dimension
T1a	Tumour > 1 mm but \leq 5 mm in greatest dimension
T1b	Tumour > 5 mm but \leq 10 mm in greatest dimension
T1c	Tumour > 10 mm but \leq 20 mm in greatest dimension
T1	Tumour > 20 mm but \leq 50 mm in greatest dimension
Т3	Tumour > 50 mm in greatest dimension
T4	Tumour of any size with direct extension to the chest wall
	and/or to the skin (ulceration or skin nodules)
T4a	Extension to the chest wall, not including only pectoralis
	muscle adherence/invasion
T4b	Ulceration and/or ipsilateral satellite nodules and/or aedema
	(including peau d'orange) of the skin, which do not meet the
	criteria for inflammatory carcinoma
T4c	Both T4a and T4b
T4d	Inflammatory carcinoma
Regional lymph	
nodes (N)	
NX	Regional lymph nodes cannot be assessed (for example,
	previously removed)
NO	No regional lymph node metastases
N1	Metastases to movable ipsilateral level I, II axillary lymph
	node(s)
N2	Metastases in ipsilateral level I, II axillary lymph nodes that
	are clinically fixed or matted; or in clinically detected
	ipsilateral internal mammary nodes in the absence of
	clinically evident axillary lymph node metastases
N2a	Metastases in ipsilateral level I, II axillary lymph nodes
	fixed to one another (matted) or to other structures
N2b	Metastases only in clinically detected ipsilateral internal
	mammary nodes and in the absence of clinically evident
	level I, II axillary lymph node metastases
N3	Metastases in ipsilateralinfraclavicular (level III axillarv)
	lymph node(s) with or without level I. II axillary lymph
	node involvement: or in clinically detected insilateral
	internal mammary lymph node(s) with clinically evident

	level I, II axillary lymph node metastases; or metastases in
	ipsilateral supraclavicular lymph node(s) with or without
	axillary or internal mammary lymph node involvement
N3a	Metastases in ipsilateralinfraclavicular lymph node(s)
N3b	Metastases in ipsilateral internal mammary lymph node(s) and axillary lymph node(s)
N3c	Metastases in ipsilateral supraclavicular lymph node(s)
Distant metastases	
(M)	
M0	No clinical or radiographic evidence of distant metastases
cM0 (i+)	No clinical or radiographic evidence of distant metastases,
	but deposits of molecularly or microscopically detected
	tumour cells in circulating blood, bone marrow, or other
	nonregional nodal tissue that are no larger than 0.2 mm in a
	patient without symptoms or signs of metastases
M1	Distant detectable metastases as determined by classic
	clinical and radiographic means and/or histologically proven
	larger than 0.2 mm

Table 1.2: Clinical staging-American Joint Commission on Cancer (7th Edition, 2009)

	• 1	- 1	•	
011	10	<u> 1</u>	111	00
УП		C I		
5~		•••		00
<u> </u>				

Stage	Т	Ν	Μ
Stage 0	Tis	N0	M0
Stage IA	T1	N0	M0
Stage IB	TO	N1mi	M0
	T1	N1mi	M0
Stage IIA	T0	N1	M0
	T1	N1	M0
	T2	N0	Mo
Stage IIB	T2	N1	M0
	T3	N0	M0
Stage IIIA	T0	N2	M0
	T1	N2	M0
	T2	N2	M0
	T3	N1	M0
	T3	N2	M0
Stage IIIB	T4	N0	M0
	T4	N1	M0
	T4	N2	M0
Stage IIIC	Any T	N3	M0
Stage IV	Any T	Any N	M1

Table 1.1 and Table 1.2 were adapted from Shah et al., (2014)

1.7 Management and treatment of breast cancer

Breast cancer is curable and treatable if detected early. The management and treatment of breast cancer depends on several factors including physical and biological characteristics of the disease, age, overall health and personal preferences of the patient. In treatment options, breast cancer is usually treated with surgery, chemotherapy, radiotherapy, hormonal and targeted therapies (Kabel and Baali, 2015)

Surgery is the main treatment in breast cancer and depends on the type and stage of tumour. Patients will undergo lumpectomy or mastectomy. Lumpectomy is a surgical procedure in which only the part of the breast containing the cancer is removed, whereas mastectomy is a surgery in which the entire breast is removed, including all the breast tissue and sometimes other nearby tissues. On the other hand, a surgery such as sentinel lymph node biopsy (SLNB) or axillary lymph node dissection (ALSD) can also be done to determine the possibility of whether breast cancer has spread to axillary lymph nodes.

Chemotherapy is a treatment where cancer cells are killed using single or combination of cytotoxic drugs either via intravenous or oral route. Usually, chemotherapy is administered to patients before, after or in place of surgery based on the stage of cases. Neoadjuvant chemotherapy is given to the patients before surgery to reduce or shrink the tumour size before undergoing surgery. On the other hand, adjuvant chemotherapy is given after the patients undergo surgery to improve the disease-free survival (DFS) and overall survival (OS) rates. Radiotherapy uses high energy rays such as X-ray or other particles to kill cancer cells or to stop the cancer cell from growing. There are two types of radiation given to breast cancer patients 1) external beam radiation and 2) internal radiation. Radiotherapy will be given to breast cancer patients following breast conserving surgery, mastectomy or when cancer cells has spread to other parts of the body.

Hormonal therapy is beneficial for breast cancer patients who are positive for oestrogen and progesterone receptor hormones. The therapy is given after or sometimes before surgery. Oestrogen has been known as an important factor for cancer cell growth and spread. Hormone therapy acts by lowering oestrogen levels or by stopping the oestrogen production, thus reducing the risk of cancer recurrence. It is recommended to breast cancer patients who are hormone positive (ER positive and/or PR positive) where tamoxifen is one of the drugs used in hormonal therapy acting by blocking the oestrogen receptors on breast cancer cells.

Researchers have developed a new drug that can be targeted or specific to the targeted cells or protein by blocking the growth and spread of cancer cells. Targeted therapy is generally less likely than chemotherapy to harm normal, healthy cells. Breast cancer patients who are positive for human epidermal growth factor-2 (HER2) are normally recommended for targeted hormone treatment.

1.8 Breast cancer prevention

Cancer prevention is the way to stop or reduce the risk of cancer development. One of the best ways to combat cancer is to prevent it from occurring by identifying and controlling the factors that may increase the risk for breast cancer development. As stated earlier, genetic and environmental factors or combinations of these two factors are closely related with higher risk of breast cancer.

By routine practice of physical activity and healthy diet, one can reduce the risk of breast cancer. Physical activities can increase the rate of metabolism and oxygen uptake. It can also can increase metabolic efficiency and capacity and help to reduce blood pressure, insulin resistance as well as obesity. Increased intake of vegetables, fruits with high antioxidant and phytochemicals in diet and avoiding fatty foods, cigarette smoking as well as alcohol may also help lower the risk of breast cancer.

Besides that, systematic screening and surveillance programmes could be addressed in order to fight against as well as reduce the mortality of breast cancer. Individuals who have family history of cancer, exposure to environmental carcinogens and common symptoms of breast cancer as mentioned earlier, should be more alertful and should take prudent steps to practise healthy lifestyles by monitoring their healths and undergoing routine medical check-up and cancer screening programmes. Breast cancer is treatable and curable if detected early. Early detection and early treatment may help to reduce the incidence and mortality rate of breast cancer.

12

1.9 Present study: Problem statement

Triple negative breast cancer (TNBC) is one of the breast cancer subtypes, characterized by lack of ER, PR expressions and no amplification of the HER-2 receptors. This subtype accounts for 15-20% of all breast cancer cases. TNBC is typically associated with high histological grade and stage, aggressive tumour phenotype showing only partial response to chemotherapy with lack of clinical established therapies (Kaplan *et al.*, 2009). Moreover, TNBC is strongly associated with distant recurrence, visceral metastases and death when compared to other breast cancer types (Bauer *et al.*, 2007; Dent *et al.*, 2007). TNBC accounts for 15%-20% of the 500,000-breast cancer associated female deaths worldwide, each year and is considered as an international public health issue (Cancer Genome Atlas, 2012). In TNBC, recurrence often occurs within 1 to 3 years of diagnosis, while 5 years mortality rates appear to be increased following initial diagnosis. The median survival of advanced TNBC is at best 12 months, much lower than the median survival observed in other advanced breast cancer subtypes (Anders and Carey, 2009).

Due to lack of target receptors (ER, PR and HER2) and lack of specific targets for treatment, patients diagnosed with TNBC do not benefit from hormonal or targeted therapy and has a high probability of having early tumour relapse following diagnosis. There has always been continuous search for novel therapeutic targets. Although effective tailored therapies have been developed for patients with hormone positive and HER-2 positive disease, TNBC patients are unlikely to benefit from currently available systemic therapy. At Hospital Universiti Sains Malaysia (Hospital USM) and several other centres, TNBC patients are treated with Taxane, Adriamycin and

Cyclophosphamide (TAC) chemotherapy regimen. TNBC seems to be particularly chemosensitive to taxanes and anthracyclines which is part of the standard regimens used for high risk patients. Since this subtype is associated with high risk of recurrence and metastasis, adjuvant chemotherapy using TAC regimen is given for early TNBC cases after the patients undergo primary surgical resection of their breast tumour and axillary nodes. Nevertheless, TNBC is generally susceptible to chemotherapy initially where early complete response does not correlate with overall survival. The risk of relapse within 3-5 years is higher than other breast cancer subtypes (Cheang *et al.*, 2008; Hudis and Gianni, 2011).

TNBC is particularly lethal when it recurs. Drug resistance or disease recurrence is a major clinical manifestation and is the principle cause of TNBC related deaths. Due to tumour heterogeneity and interindividual differences in TNBC patients, the efficacy and toxicity of TAC chemotherapeutic drugs vary across individuals. As a result, a significant number of TNBC patients fail to respond or acquire resistance to the introduced TAC chemotherapeutic agents that usually leads to a relapse and worsening of prognosis. It has been shown that one out of two patients will fail to respond to initial treatments or will rapidly acquire resistance to chemotherapeutic drugs (O'Driscoll and Clynes, 2006). Since TNBC lacks specific target and clinical therapies, the availability of markers or signals that reliably differentiates between TAC chemotherapy sensitive and resistant patients are required to improve the chemotherapy.

In predicting the disease progression, the prospect of recurrence and treatment response, traditional clinical risk factors such as tumour size, patient's age, regional lymph node spread, and ER receptor status are commonly used (Early Breast Cancer Trialists' Collaborative *et al.*, 2008). However, the information derived from all these parameters are often unreliable in identifying who will respond better with TAC chemotherapy from others and who may end up with poor outcomes and recurrences. The causes for TNBC recurrence remain unknown. There is no acceptable module to investigate drug resistance and disease recurrence in TNBC. Hence, there is a pressing need to identify markers for TAC chemotherapy response in TNBC patients. This study aimed to investigate few putative genetic markers for their possible role in determining the TAC chemotherapy response, recurrence risk and treatment outcomes.

1.9.1 Genetic determinants of variable chemotherapy response and recurrence risk

Once the chemotherapeutic drugs enter a patient's system and transits through the body to interact with cancer cell, the drugs interact with a diversity of molecular entities. During this process, patient's genetics, especially germline-based variations can affect the pharmacokinetics of chemotherapeutic drugs and thus influence the bioavailability of these drugs. Pharmacokinetic variability also accounts for suboptimal therapeutic drug levels which results in decreased response. The factors accounting for suboptimal drug levels include variable metabolizing activities as well as different transporter activities. Genetic variations in the form of single nucleotide polymorphism (SNPs) that affect gene expression or function in individuals can cause interindividual differences in the metabolism and disposition of medications. Genetic variations in genes encoding drug metabolizing enzymes and drug transporters could affect expression of corresponding proteins and can impact pharmacokinetics of chemotherapeutic drugs in patients and thereby may influence the intracellular delivery, effectiveness and response to those drugs.

To date, genomic assays may be helpful in differentiating interpatient variability in identifying breast cancer patients who are likely to benefit (or not) and also in predicting disease recurrence. Genetic and epigenetic factors have been shown to be attributable to TNBC chemoresistance (O'Reilly *et al.*, 2015; Ouyang *et al.*, 2014). Differences in genetic variation among breast cancer patients have been identified to be important factors that contribute to differences in treatment response. SNPs of pharmacogenes might lead to absence or altered enzyme activity and show an impact on individual's response or resistance to the treatment (Dumont *et al.*, 2015). SNPs may affect drug toxicity and efficacy in a variety of ways. For example, SNPs located in coding sequence of a gene may result in amino acid change that may alter protein function when compared to wildtype protein.

Drug transporters regulate the influx and efflux of drugs in cells. Genetic polymorphisms of transporters can have profound impact on drug disposition, drug efficacy and drug safety and thereby impact pharmacokinetics (Franke *et al.*, 2008). Of particular interest has been on the pharmacogenetic relevance due to genetic variation in efflux transporters of the ATP-binding cassette (ABC) subfamily member B1 (*ABCB1*). As a transporter, *ABCB1* has a broad affinity spectrum for different anticancer drugs including docetaxel, paclitaxel, doxorubicin etc.

Metabolism of a drug can also contribute to therapy resistance. The cytochrome P450 (CYPs) enzymes facilitate the metabolism and elimination of nearly 50% of all chemotherapeutics drugs. In the metabolism of the drugs used in TAC chemotherapy regimen, the *CYP3A4*, *CYP3A5* and *CYP1B1* play major role. Genetic variations in the above CYP genes also can have profound effect on enzymes activity and thereby contribute to the variations in response to the chemotherapeutic drugs used for TNBC patients.

Because genetic polymorphisms may affect the expression and activity of encoded proteins, it is a key covariate that is responsible for variability in drug metabolism, drug transport and for determining pharmacodynamics of drug effects. Cytochrome P450 (*CYP1B1*, *CYP3A4* and *CYP3A5*) are drug metabolism enzymes and *ABCB1* is drug efflux transporter that have been widely studied. SNPs in these drug metabolism and transport genes that may alter protein function are suggested to play an important role in determining the effectiveness of drugs and also in determining why some individuals are responsive or resistant to chemotherapeutic drugs. Since no reports are available on the impact of genetic variations in these drug metabolising or transporter genes on TAC chemotherapy response in TNBC patients, it was of interest to investigate whether genetic variations [SNPs] in *CYP1B1* [142 C>G (rs10012), 4326 C>G (rs1056836) and 4390 A>G (rs1800440)], *CYP3A4* [878 T>C (rs28371759)], *CYP3A5* [6986 A>G (rs776746)], *ABCB1* [1236 C>T (rs1128503), 2677 G>T/A (rs2032582) and 3435 C>T (rs1045642)] have any impact in modulating TAC chemotherapy response and treatment outcome in TNBC patients.

Gene expression also plays an important role in chemotherapeutic response. For example, mRNA regulation is a process where the production of specific gene is increased or decreased. Deregulation of gene expression might play an important role in chemotherapeutic response. Alteration in drug metabolizing and transporter genes may reduce or increase the gene expression, and thus inactivate (or activate) the gene function. Hence, it was aimed to determine the mRNA expression levels of *CYP1B1*, *CYP3A4*, *CYP3A5* and *ABCB1* in cancerous as well as normal adjacent tissues and to correlate the gene expression levels with TAC chemotherapy response and treatment outcome in TNBC patients.

Another aspect is epigenetic factors which also play important role in pharmacological response of chemotherapeutic drugs. Epigenetic factors such as microRNAs (miRNAs) represents a class of naturally occurring small non-coding RNA molecules. Through down regulating the expression of target genes, miRNAs play an important role in various biological processes including the proliferation, metastasis and chemoresistance of TNBC (Bockhorn *et al.*, 2013). The silencing mechanism by which miRNAs regulate the expression of other genes might be one of the key factors regulating the cell specific expression as well as individual differences in the gene expression. Because of their high stability and specific expression pattern during tumorigenesis and progression, miRNAs have become attractive candidate biomarkers for cancer diagnosis and prognosis and novel target for cancer treatment. It has been shown that alterations in miRNA expression properties can be used to estimate and monitor the success of different therapeutic modalities (Zheng *et al.*, 2010) and hence

miRNA expression are attractive novel aspects which can explain interindividual differences in drug response. Therefore, it was of interest to study few selected miRNAs with possible implications in modulating TAC chemotherapy response, predicting TNBC recurrence and treatment outcome. This study aimed to investigate the expression levels of selected miRNAs (miR-21, miR-27b, miR-34a, miR-182, miR-200c and miR-451) in cancerous and normal adjacent tissues and to correlate the miRNA expression levels with TAC chemotherapy response and treatment outcome in Malaysian TNBC patients.

It was hypothesized that, an individual's genomic profile especially genetic variations such as SNPs, expression of mRNAs and miRNAs within tumour samples may be able to identify characteristics that reflect tumour behaviour, response to treatment, disease progression and treatment outcome. Even though several studies have focused on the role of drug transporter and metabolism genes in genetic susceptibility to cancer, very little progress has been made in the identification of genetic and pharmacogenetic markers in modulating chemoresistance in TNBC patients. Therefore, the availability of genetic determinants that reliably differentiate between the chemotherapy regimensensitive and resistant patients would improve breast cancer therapy. Currently, there are no genetic determinants available to predict the response of TNBC patients to TAC chemotherapy before initiation of treatment. It was hoped that this study which focuses on epigenetic (selected miRNAs expression) and pharmacogenetic alterations in drug metabolizing and drug transport enzymes (SNPs and mRNA expression) in TNBC patients undergoing (TAC) chemotherapy regimen might generate new information in this direction.

1.9.2 Objective(s) of the study

The main objective of this study was to investigate the impact of selected SNPs of *CYP1B1, CYP3A4, CYP3A5* and *ABCB1*, their mRNAs expression and expression levels of selected miRNAs in modulating TAC chemotherapy response and treatment outcome among TNBC patients.

The specific objectives were:

- To investigate the genotype, allele and haplotype frequencies of the following polymorphisms (*CYP1B1* 142 C>G (rs10012), 4326 C>G (rs1056836) and 4390 A>G (rs1800440), *CYP3A4* 878 T>C (rs28371759), *CYP3A5* 6986 A>G (rs776746), *ABCB1* 1236 C>T (rs1128503), 2677 G>T/A (rs2032582) and 3435 C>T (rs1045642) in TNBC patients undergoing chemotherapy with TAC and determine the association of the genotypes and haplotypes of the investigated SNPs with chemotherapy response in TNBC patients.
- To investigate the mRNA expression level of *CYP1B1*, *CYP3A4*, *CYP3A5*, *ABCB1* in cancerous and non-cancerous tissues of TNBC patients and to determine their association with clinicopathological variables and chemotherapy response
- 3. To investigate the expression levels miRNAs (miR-21, miR-27b, miR-34a, miR-182, miR-200c and miR-451) in cancerous and non-cancerous tissues of triple negative breast cancer tissue patients and determine their contributory role in modulating chemotherapy response in TNBC patients.

- 4. To correlate the SNPs genotype pattern, mRNA and miRNA expression levels as well as clinicopathological variables with the relapse-free survival and overall survival of TNBC patients and evaluate their clinical significance.
- 5. To evaluate whether all the above parameters could serve as predictive biomarkers of chemotherapy response and treatment outcome in TNBC patients undergoing TAC chemotherapy.

1.9.3 Hypothesis

Alternate hypothesis: There is association between candidate SNPs and mRNA expressions of *CYP1B1*, *CYP3A4*, *CYP3A5* and *ABCB1* and expression of selected miRNAs with TAC chemotherapy response in TNBC patients.

CHAPTER 2

LITERATURE REVIEW

2.1 Triple negative breast cancer (TNBC)

Breast cancer is a heterogenous disease encompassing a variety of morphological and clinical distincts. As discussed in Chapter 1, breast cancer can be divided into five subtypes; luminal A, luminal B, HER-2 over expression, basal like and normal breast-like. TNBC is defined by the lack of ER, PR expression and no amplification of HER-2 (Elias, 2010). The term TNBC is referred to the immunohistochemically classified breast cancer showing absence of ER, PR and HER-2 protein expressions whereas the basal like subtype is defined by gene expression microarray analysis. TNBC is often but not always basal-like breast cancer (lack of ER, PR and HER-2 expressions), although there is a substantial overlap between TNBC tumour and basal like breast cancer (BLBC). There is significant heterogeneity within these largely overlapping subtypes (Turner *et al.*, 2010). Seventy-five (75%) of BLBC is TNBC subtype and 70% of TNBC is BLBC (Carey *et al.*, 2006). On the other hand, most of BRCA-1 mutant breast cancers are both TNBC and BLBC (Figure 1.3).



Figure 2.1: Similarities of TNBC, BLBC and BRCA-1 breast cancer (adapted from Hulsen *et al.*, 2008)

2.1.1 Incidence of TNBC

Worldwide, the incidence of TNBC represents approximately 15-20% of newly diagnosed breast cancer cases (Bauer *et al.*, 2007) where 170,000 of TNBC cases are diagnosed annually. The incidence of TNBC is higher in African-American women than other ethnic groups (Whites and Hispanics) (Clarke *et al.*, 2012). The African-American women had two-fold higher (4.1 per 100,000) incidence of TNBC than White (2.2 per 100,000) or Hispanic (2.1 per 100,000) (Amirikia *et al.*, 2011).

In Malaysia, the incidence of TNBC has been reported to range from 12.3% to 17.6% of the total breast cancer cases (Kanapathy Pillai *et al.*, 2012; Tan *et al.*, 2009). In other

population, the incidence of TNBC reported was 11.2% in Canada (Dent *et al.*, 2007), 13.0% in Singapore (Thike *et al.*, 2010), 16.3% in United Kingdom (Rakha *et al.*, 2007), 14.0% in Japan (Nishimura and Arima, 2008), 20.4% in China (Qiu *et al.*, 2016a) and 19.9% in India (Patil *et al.*, 2011). This indicates the disparity in TNBC incidence between the different ethnic groups in different countries.

2.1.2 Risk factors associated with TNBC

Some of the risk factors associated with TNBC development has already been mentioned in Chapter 1. However, there are several other risk factors reported to be associated higher risk of TNBC. TNBC frequently affects younger women. A study has shown that women under the age of 40 years had two-fold higher risk of being diagnosed as TNBC than women over 50 years of age. In addition, the age at diagnosis for TNBC is 5-10 years younger than non-TNBC patients (Newman *et al.*, 2015; Trivers *et al.*, 2009). Moreover, TNBC is reported to be more common in black women as compared to Whites (Trivers *et al.*, 2009). In addition, African-American women had two times higher risk of getting TNBC compared to Whites and Hispanics (Amirikia *et al.*, 2011).

TNBC is overlapped with BRCA1 mutant breast cancer subtype. Thus, women with *BRCA1* mutations have more than 50.0% chance of developing TNBC (Zhang *et al.*, 2012). A study by Gonzalez-Angulo *et al.* (2011) indicated that 20.0% of TNBC patients have positive *BRCA1* mutations. Another study on Mexican TNBC patients showed that 23.0% of the patients had *BRCA1* mutations (*BRCA1* ex9-12del) (Villarreal-Garza *et al.*, 2015). On the other hand, methylation at the promoter region